/GNLX
GNLX Stock - Genelux Corporation
Healthcare|BiotechnologyNASDAQ
$4.20+0.24%
+$0.01 (+0.24%) • Dec 19
77
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.49
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+312.6%upside
Target: $17.33
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for GNLX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.16 – $4.24
TARGET (TP)$17.33
STOP LOSS$3.86
RISK/REWARD1:38.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.05
52W High$8.54
52W Low$1.99
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $8,000 | $170,000 | $11.07M | N/A | N/A |
| Gross Profit | $-895,000 | $-848,000 | $10.10M | $-895,000 | $-658,000 |
| Gross Margin | -11187.5% | -498.8% | 91.3% | N/A | N/A |
| Operating Income | $-31,696,000 | $-24,165,000 | $-3,013,000 | $-14,613,000 | $-12,422,000 |
| Net Income | $-29,869,000 | $-28,297,000 | $-5,207,000 | $-17,795,000 | $-14,864,000 |
| Net Margin | -373362.5% | -16645.3% | -47.0% | N/A | N/A |
| EPS | $-0.95 | $-1.16 | $-0.21 | $-0.69 | $-0.58 |
Company Overview
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
6 Bullish0 Neutral/Bearish
Price Targets
$20
Average Target
↑ 372.2% Upside
Now
$8
Low
$20
Average
$40
High
Based on 6 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 21st 2025 | Lake Street | Initiation | Buy | $16 |
| October 29th 2024 | Guggenheim | Initiation | Buy | $8 |
| August 28th 2024 | ROTH MKM | Initiation | Buy | $10 |
| November 27th 2023 | H.C. Wainwright | Initiation | Buy | $35 |
| September 12th 2023 | Maxim Group | Initiation | Buy | $40 |
| February 15th 2023 | The Benchmark Company | Initiation | Speculative Buy | $10 |
Earnings History & Surprises
GNLXBeat Rate
33%
Last 12 quarters
Avg Surprise
-34.4%
EPS vs Estimate
Beats / Misses
4/7
1 met exactly
Latest EPS
$-0.21
Q4 2025
EPS Surprise History
Q1 24
-19.0%
$-0.25vs$-0.21
Q2 24
-26.1%
$-0.29vs$-0.23
Q3 24
-15.8%
$-0.22vs$-0.19
Q4 24
0.0%
$-0.19vs$-0.19
Q1 25
-52.9%
$-0.26vs$-0.17
Q2 25
+12.5%
$-0.21vs$-0.24
Q3 25
+9.1%
$-0.20vs$-0.22
Q4 25
+8.7%
$-0.21vs$-0.23
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 27, 2026 | $-0.22 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.23 | $-0.21 | +8.7% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.22 | $-0.20 | +9.1% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $-0.24 | $-0.21 | +12.5% | ✓ BEAT |
Q1 2025 | Mar 28, 2025 | $-0.17 | $-0.26 | -52.9% | ✗ MISS |
Q4 2024 | Nov 14, 2024 | $-0.19 | $-0.19 | 0.0% | = MET |
Q3 2024 | Aug 14, 2024 | $-0.19 | $-0.22 | -15.8% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.23 | $-0.29 | -26.1% | ✗ MISS |
Q1 2024 | Mar 29, 2024 | $-0.21 | $-0.25 | -19.0% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-0.12 | $-0.20 | -66.7% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-0.15 | $-0.23 | -53.3% | ✗ MISS |
Q2 2023 | May 15, 2023 | $-0.16 | $-0.53 | -230.9% | ✗ MISS |
Q1 2023 | Jan 26, 2023 | $-0.17 | $-0.13 | +22.1% | ✓ BEAT |
Q3 2022 | Sep 30, 2022 | — | $0.16 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.13 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.13 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.12 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.14 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.31 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.10 | — | — |
Frequently Asked Questions about GNLX
What is GNLX's current stock price?
Genelux Corporation (GNLX) is currently trading at $4.20 per share. The stock has moved +0.24% today.
What is the analyst price target for GNLX?
The average analyst price target for GNLX is $17.33, based on 1 analyst.
What sector is Genelux Corporation in?
Genelux Corporation operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is GNLX's market cap?
Genelux Corporation has a market capitalization of $0.16 billion, making it a small-cap company.
Does GNLX pay dividends?
No, Genelux Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACIU
AC Immune S.A.
$3.03
Mkt Cap: $0.3B
ALDX
Aldeyra Therapeutics, Inc.
$4.96
Mkt Cap: $0.3B
CADL
Candel Therapeutics, Inc.
$5.57
Mkt Cap: $0.3B
CLLS
Cellectis S.A.
$4.37
Mkt Cap: $0.4B
CTNM
Contineum Therapeutics, Inc. Class A Common Stock
$11.74
Mkt Cap: $0.3B
DRTS
Alpha Tau Medical Ltd.
$5.07
Mkt Cap: $0.4B
LXEO
Lexeo Therapeutics, Inc. Common Stock
$10.35
Mkt Cap: $0.8B
LYEL
Lyell Immunopharma, Inc.
$33.33
Mkt Cap: $0.7B
MREO
Mereo BioPharma Group plc
$2.00
Mkt Cap: $0.3B
SLN
Silence Therapeutics plc
$6.37
Mkt Cap: $0.3B
Explore stocks similar to GNLX for comparison